<DOC>
	<DOCNO>NCT00619866</DOCNO>
	<brief_summary>This study design see research compound ( NBI- 56418 ) work compare placebo ( also know sugar pill ) woman endometriosis see effect , , bone mineral density .</brief_summary>
	<brief_title>An Efficacy Safety Study NBI-56418 Endometriosis</brief_title>
	<detailed_description>This Phase II , multicenter , randomize , double-blind , placebo-controlled parallel-group study assess efficacy safety NBI-56418 two dose level administer daily 6 month . Approximately 150 subject randomize ( 1:1:1 ) one follow treatment group first 12 week dose : 150 mg NBI-56418 q.d . ; 250 mg NBI-56418 q.d ; placebo q.d . Following 12 week dose , subject continue study additional 12 week ; subject randomize NBI-56418 continue receive assign dose subject randomize placebo re-randomized receive one two dose NBI-56418 12 week double-blind fashion . The effect NBI-56418 treatment bone mineral density ( BMD ) follow 6 month treatment NBI-56418 .</detailed_description>
	<mesh_term>Endometriosis</mesh_term>
	<criteria>Inclusion Criteria Be female , age 18 49 year , inclusive Have moderate severe pelvic pain due endometriosis Have surgically ( laparoscopy ) diagnose endometriosis within last 8 year recurrent persistent endometriosis symptom Have regular menstrual cycle Have Body Mass Index ( BMI ) 18 36 kg/m2 , inclusive Agree use two form nonhormonal contraception study Exclusion Criteria Are currently receive GnRH agonist GnRH antagonist receive agent within 6 month start screen Are currently receive DMPASC DMPAIM receive agent within 3 month start screen Are currently use hormonal contraception form hormonal therapy receive treatment within last month Have surgery endometriosis within last month Have hysterectomy bilateral oophorectomy Are use systemic steroid chronic regular basis within 3 month Have uterine fibroid â‰¥3 cm diameter Have pelvic pain cause endometriosis Have unstable medical condition chronic disease Have pregnant within last six month Currently breast feed</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>bone mineral density</keyword>
	<keyword>NBI-56418</keyword>
	<keyword>estradiol</keyword>
	<keyword>Endometriosis</keyword>
	<keyword>Pelvic Pain</keyword>
</DOC>